Sharescart Research Club logo

Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹1588 Cr.
Stock P/E
31.2
P/B
4.3
Current Price
₹549.3
Book Value
₹ 128.1
Face Value
1
52W High
₹790
52W Low
₹ 490
Dividend Yield
0.89%

Amrutanjan Healthcar Overview

1. Business Overview

Amrutanjan Health Care Ltd. is an Indian consumer healthcare company primarily engaged in the manufacturing and marketing of Ayurvedic and Over-The-Counter (OTC) products. Established in 1893, it is one of India's oldest companies in its segment. Its core business revolves around providing relief-oriented products for common ailments like pain, cold, and cough, alongside a growing portfolio of health and wellness products. The company makes money by selling these products through an extensive distribution network across India, including pharmacies, general stores, and modern trade channels, leveraging its strong brand heritage.

2. Key Segments / Revenue Mix

Amrutanjan's business is broadly categorized into:

Pain Management: This is the flagship segment, dominated by products like Amrutanjan Pain Balm, Joint Muscle Spray, and creams for various types of pain. This segment typically contributes the largest share of revenue.

Cough & Cold: Includes products like Amrutanjan Cold Rub and roll-ons designed to alleviate cold and flu symptoms.

Health & Wellness: This growing segment encompasses products such as Fruitnik health drinks, hand sanitizers, and other personal care items, aiming to diversify beyond traditional relief products.

Exact percentage contributions vary year-on-year, but Pain Management historically remains the dominant revenue driver.

3. Industry & Positioning

Amrutanjan operates within the highly competitive Indian consumer healthcare and OTC pharmaceuticals market. This industry is characterized by a mix of large multinational corporations, domestic FMCG giants, and specialized Ayurvedic players. Amrutanjan holds a strong legacy position, particularly in the pain relief balm category, where its brand is a household name. It competes with players like Emami (Zandu Balm), Reckitt Benckiser (Moov), P&G (Vicks), Dabur, and Himalaya. Its positioning is built on a century-old heritage, trust in Ayurvedic formulations, and extensive distribution reach, especially in semi-urban and rural areas.

4. Competitive Advantage (Moat)

Amrutanjan possesses several durable competitive advantages:

Brand Recognition & Heritage: Over 125 years of existence has built immense brand recall and trust, particularly for its pain balms, making "Amrutanjan" almost synonymous with the product category for many consumers.

Extensive Distribution Network: A deep and wide distribution network across India ensures product availability even in remote locations, a significant barrier to entry for new players.

Consumer Loyalty: Generations of consumers have used and trusted Amrutanjan products, leading to strong brand loyalty, especially for its core offerings.

Formulation Expertise: A long history of developing and refining Ayurvedic formulations gives it credibility in traditional remedies.

5. Growth Drivers

Key factors that can drive Amrutanjan's growth include:

Increasing Health & Wellness Awareness: Growing consumer focus on preventive healthcare and natural remedies fuels demand for its Ayurvedic and wellness products.

Product Portfolio Expansion: Launching new products in existing categories (e.g., specialized pain relief) and expanding into adjacent health and hygiene segments.

Deepening Market Penetration: Further expanding its distribution reach into untapped rural markets and strengthening presence in modern retail and e-commerce channels.

Premiumization: Introducing higher-value or specialized products that command better margins.

Demographic Shifts: An aging population could increase demand for pain management solutions.

6. Risks

Intense Competition: Facing stiff competition from well-funded domestic and international FMCG and pharmaceutical companies that have vast marketing budgets and distribution capabilities.

Raw Material Price Volatility: Fluctuations in the prices of key Ayurvedic and natural ingredients can impact production costs and profitability.

Changing Consumer Preferences: A shift towards modern medicine, different forms of natural remedies, or alternative wellness trends could impact demand for traditional products.

Regulatory Changes: Any changes in regulations related to manufacturing, marketing, or labeling of Ayurvedic and OTC products in India.

Counterfeit Products: Risk of fake products eroding brand trust and market share.

7. Management & Ownership

Amrutanjan Health Care Ltd. is a promoter-driven company, with the Sambhu Prasad family holding a significant stake and actively involved in its management. Mr. S. Sambhu Prasad serves as the Chairman and Managing Director. The management is generally perceived as conservative, focused on sustainable growth, and maintaining the company's long-standing heritage. The promoter holding typically hovers around 50-60%, indicating strong family control and alignment with long-term vision.

8. Outlook

Amrutanjan Health Care has a resilient business built on a foundation of strong brand equity and an extensive distribution network, particularly for its heritage pain management products. The company is strategically diversifying its product portfolio into the growing health and wellness segment, which offers avenues for future growth beyond its traditional core. While it operates in a highly competitive market against larger players, its established brand trust and Ayurvedic legacy provide a distinct advantage. The outlook suggests steady, albeit potentially moderate, growth driven by an expanding product range and increasing consumer demand for accessible, trusted healthcare solutions, balanced by the need to innovate and compete effectively against agile rivals.

Amrutanjan Healthcar Share Price

Live · BSE / NSE · Inception: 1936
| |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Amrutanjan Healthcar Quarterly Results

#(Fig in Cr.) Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 117 127 84 110 123 135 94 118 141 150
Other Income 4 5 4 4 4 5 4 4 4 5
Total Income 121 132 88 114 127 140 98 122 145 154
Total Expenditure 95 111 80 96 99 118 86 101 116 124
Operating Profit 25 21 8 18 28 23 13 21 29 30
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 2 2 2 2 2 2 2 2 2 2
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 -1 -8
Profit Before Tax 24 20 6 16 26 21 11 19 26 21
Provision for Tax 6 6 2 4 7 6 3 5 7 5
Profit After Tax 17 14 5 12 19 15 8 14 19 16
Adjustments -0 0 0 0 0 0 0 0 0 -0
Profit After Adjustments 17 14 5 12 19 15 8 14 19 16
Adjusted Earnings Per Share 6 4.7 1.6 4.1 6.7 5.3 2.9 4.8 6.7 5.6

Amrutanjan Healthcar Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 163 184 212 220 253 261 333 406 380 421 452 503
Other Income 5 6 7 8 7 8 19 17 15 16 18 17
Total Income 168 190 219 228 261 270 352 423 394 438 469 519
Total Expenditure 139 153 182 192 222 231 266 328 335 369 394 427
Operating Profit 29 37 37 36 38 39 86 95 59 68 76 93
Interest 1 0 1 0 0 0 1 1 0 0 0 0
Depreciation 2 3 3 3 3 4 4 4 5 6 7 8
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 -9
Profit Before Tax 26 35 34 33 35 34 82 91 54 62 69 77
Provision for Tax 9 12 12 13 10 9 21 23 14 17 18 20
Profit After Tax 17 22 22 20 25 25 61 67 40 45 51 57
Adjustments 0 0 0 -0 0 0 0 0 0 0 0 0
Profit After Adjustments 17 22 22 20 25 25 61 67 40 45 51 57
Adjusted Earnings Per Share 5.9 7.7 7.5 6.9 8.4 8.6 20.9 23 13.6 15.6 17.6 20

Amrutanjan Healthcar Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 105 120 116 129 146 159 216 265 291 288 327
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 2 3 1 1 2 2 3 4 4 5 7
Total Current Liabilities 23 25 32 32 36 39 52 77 63 70 85
Total Liabilities 130 149 149 162 183 201 271 346 358 364 418
Fixed Assets 13 22 27 28 26 26 23 28 49 50 49
Other Non-Current Assets 39 32 13 13 18 49 25 43 49 18 78
Total Current Assets 79 95 108 121 140 126 223 275 260 296 291
Total Assets 130 149 149 162 183 201 271 346 358 364 418

Amrutanjan Healthcar Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 29 31 22 10 11 15 7 3 2 5 4
Cash Flow from Operating Activities 19 21 8 19 21 18 91 52 20 28 51
Cash Flow from Investing Activities -5 1 -0 -8 -11 -14 -88 -36 -2 19 -31
Cash Flow from Financing Activities -12 -11 -5 -9 -7 -12 -7 -17 -15 -48 -13
Net Cash Inflow / Outflow 2 12 3 2 3 -7 -4 -1 3 -1 6
Closing Cash & Cash Equivalent 31 42 25 11 15 7 3 2 5 4 10

Amrutanjan Healthcar Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 5.86 7.67 7.46 6.86 8.39 8.58 20.93 22.99 13.63 15.56 17.58
CEPS(Rs) 6.66 8.53 8.44 7.85 9.5 10.07 22.19 24.28 15.41 17.65 19.84
DPS(Rs) 1.75 1.93 1.93 1.95 2.15 2.1 4.2 4.6 4.6 4.6 4.6
Book NAV/Share(Rs) 35.87 41.22 39.59 44.01 49.86 54.54 73.53 90.49 99.12 99.92 112.83
Core EBITDA Margin(%) 14.37 16.33 13.41 12.77 12.21 11.79 20.2 19.11 11.73 12.32 12.91
EBIT Margin(%) 15.75 17.99 15.41 15.02 13.77 13.31 24.79 22.46 14.19 14.77 15.37
Pre Tax Margin(%) 15.39 17.89 15.16 14.88 13.69 13.18 24.61 22.32 14.13 14.71 15.3
PAT Margin (%) 9.98 11.6 9.82 9.05 9.67 9.59 18.38 16.56 10.49 10.68 11.25
Cash Profit Margin (%) 11.36 12.91 11.12 10.36 10.96 11.26 19.49 17.49 11.87 12.11 12.7
ROA(%) 13.45 16.07 14.66 12.89 14.18 13.05 25.94 21.78 11.32 12.47 13
ROE(%) 16.97 19.9 18.46 16.41 17.87 16.44 32.69 28.03 14.37 15.54 16.53
ROCE(%) 26.06 30.86 28.65 26.95 25.43 22.8 44 37.93 19.38 21.47 22.58
Receivable days 53.45 49.61 45.1 46.65 43.86 41.46 24.19 25.15 34.26 35.05 41.89
Inventory Days 14.77 14.28 14.75 16.79 17.96 26.73 22.58 19.54 26.36 25.01 22.69
Payable days 79.48 80.83 71.56 98.06 86.35 95.43 93.75 102.26 108.19 89 102.13
PER(x) 40.85 27.21 39.57 39.2 37.05 38.45 27.15 34.53 42.19 39.77 36.67
Price/Book(x) 6.67 5.06 7.45 6.11 6.23 6.05 7.73 8.77 5.8 6.19 5.72
Dividend Yield(%) 0.73 0.92 0.65 0.73 0.69 0.64 0.74 0.58 0.8 0.74 0.71
EV/Net Sales(x) 4.05 3.05 3.94 3.24 3.26 3.55 4.57 5.5 4.24 4.18 3.94
EV/Core EBITDA(x) 22.54 15.07 22.52 19.71 21.68 23.71 17.66 23.51 27.26 25.82 23.44
Net Sales Growth(%) 17.64 12.89 14.77 3.96 15.17 3.2 27.29 21.93 -6.46 10.96 7.26
EBIT Growth(%) 17.63 28.73 -1.64 -2.71 4.87 -0.27 137.11 10.5 -40.91 15.46 11.68
PAT Growth(%) 17.85 30.98 -2.76 -8.03 22.27 2.32 143.95 9.8 -40.71 12.9 13.03
EPS Growth(%) 17.85 30.98 -2.76 -8.03 22.27 2.32 143.95 9.8 -40.71 14.15 13.04
Debt/Equity(x) 0 0 0.02 0 0 0 0 0 0 0 0
Current Ratio(x) 3.42 3.76 3.35 3.75 3.87 3.22 4.28 3.55 4.13 4.23 3.44
Quick Ratio(x) 3.1 3.44 3.04 3.43 3.46 2.61 3.94 3.21 3.67 3.82 3.11
Interest Cover(x) 43.76 173.68 61.33 106.83 172.19 102.57 139.35 156.66 241.99 247.9 213
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +7% +4% +12% +11%
Operating Profit CAGR +12% -7% +14% +10%
PAT CAGR +13% -9% +15% +12%
Share Price CAGR -23% -3% -6% +10%
ROE Average +17% +15% +21% +19%
ROCE Average +23% +21% +29% +28%

Amrutanjan Healthcar Shareholding Pattern

Latest · Mar 2026
100% held
Promoters 46.52 %
FII 2.17 %
DII (MF + Insurance) 12.66 %
Public (retail) 53.48 %
# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 50.5950.5950.5946.5246.5246.5246.5246.5246.5246.52
FII 0.81.381.552.342.32.32.412.382.272.17
DII 7.247.297.3210.611.1211.4112.712.91312.66
Public 49.4149.4149.4153.4853.4853.4853.4853.4853.4853.48
Others 0000000000
Total 100100100100100100100100100100

Amrutanjan Healthcar Peer Comparison

Pharmaceuticals & Drugs Edit Columns

Amrutanjan Healthcar Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Amrutanjan Healthcar Pros & Cons

Pros

  • Company is almost debt free.

Cons

  • Promoter holding is low: 46.52%.
  • Debtor days have increased from 89 to 102.13days.
  • Stock is trading at 4.3 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp